高脂血症和炎症在动脉粥样硬化的发生发展中起着重要作用。动脉粥样硬化被认为是动脉粥样硬化斑块形成开始时血管对损伤的炎症反应,然后导致心血管事件。几个世纪以来,红曲霉属的食用菌一直被用作东亚的传统中药。红曲霉NTU568的发酵产物具有许多功能性次级代谢产物,包括抗炎色素monascin和kankaflavin。已显示源自紫癜支原体的化合物具有降血脂作用。我们的目的是通过进行为期12周的随机研究,来评估紫癜支原体NTU568发酵产物(Ankascin568plus)对总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)处于临界高水平的志愿者的血脂的影响,双盲,安慰剂对照,自适应设计研究。这项研究从TC和LDL-C水平≥180mg/dL和130-190mg/dL的患者人群中招募了40名年龄在18-65岁之间的受试者,分别。测量的终点包括血脂谱,肝脏,肾脏和甲状腺功能,电解质平衡,肌酐磷酸激酶,和空腹血糖。治疗4周后(500mgAnkascin568+/天),脂质水平的变化表明,活性产物比安慰剂具有更有利的作用。与基线相比,TC和LDL-C水平有统计学意义的下降11.9%和19.0%,分别(所有对的p<0.05)。该研究表明,施用一个500mg的Ankascin568+胶囊超过4周的受试者表现出血清TC和LDL-C水平的显著降低。因此,Ankascin568plus可能是调节血脂和治疗冠状动脉疾病的潜在有用药物。
Hyperlipidemia and inflammation play important roles in the development and progression of atherosclerosis. Atherosclerosis is regarded as an inflammatory response of blood vessels to injury at the start of atherosclerotic plaque formation, which then leads to cardiovascular events. Edible fungi of the Monascus species have been used as traditional Chinese medicines in East Asia for several centuries. The fermented products of Monascus purpureus NTU 568 possess a number of functional secondary metabolites including the anti-inflammatory pigments monascin and
ankaflavin. Compounds derived from M. purpureus have been shown to have hypolipidemic effects. We aimed to evaluate the effects of M. purpureus NTU 568 fermentation product an extract (Ankascin 568 plus) containing monascin and
ankaflavin on blood lipids in volunteers with borderline high levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) by conducting a 12-week randomized, double-blind, placebo-controlled, adaptive-design study. This study enrolled 40 subjects aged 18-65 years from a population of patients with TC and LDL-C levels of ≥180 mg/dL and 130-190 mg/dL, respectively. Measured endpoints included lipid profile, liver, kidney and thyroid function, electrolyte balance, creatinine phosphokinase, and fasting blood glucose. After 4 weeks of treatment (500 mg Ankascin 568 plus/day), the changes in the lipid levels showed that the active products had a more favorable effect than the placebo. Compared to the baseline, statistically significant decreases of 11.9% and 19.0% were observed in TC and LDL-C levels, respectively (p < 0.05 for all pairs). This study demonstrated that subjects administered one 500 mg capsule of Ankascin 568 plus for more than 4 weeks exhibited a significant reduction in serum TC and LDL-C levels. Therefore, Ankascin 568 plus may be a potentially useful agent for the regulation of blood lipids and the treatment of coronary artery diseases.